Phase 2 Evidence and Impact Analysis
Article 1 — Pemvidutide for MASH (IMPACT trial) | PMID 43014327
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Pemvidutide is a GLP-1/glucagon dual agonist; phase 2b RCT data for MASH with non-invasive fibrosis/inflammation endpoints adds meaningfully to a crowded but rapidly evolving space. Incremental over resmetirom/semaglutide data but distinct mechanism. |
| Clinical Relevance | 8 | MASH has no broadly approved therapy beyond resmetirom (approved 2024); a second mechanistic class with 48-week RCT data showing non-invasive endpoint improvement is directly practice-informing for hepatologists. |
| Population Reach | 8 | MASH affects an estimated 15–20 million Americans and >100 million people globally, with rising prevalence tracking obesity epidemics. |
| Implementation Speed | 5 | Phase 2b only; phase 3 biopsy-confirmed endpoints required before regulatory submission. Realistically 4–7 years to approval. |
| Evidence Strength | 7 | Multicenter RCT, double-blind, placebo-controlled. Major limitation: n=41 is very small for a phase 2b; non-invasive endpoints (non-biopsy) limit interpretability; abstract only reviewed. |
Key quantitative result: Significant reductions in non-invasive tests of MASH inflammation and fibrosis at 48 weeks vs. placebo (specific HR/absolute values not available from abstract).
External validation: None yet; single trial.
Main limitation: Very small n (41); non-invasive surrogate endpoints; full biopsy-confirmed resolution data presumably pending or not primary.
Equity implications: MASH disproportionately affects Hispanic and South Asian populations and those with lower socioeconomic status. If approved, access disparities are likely given expected high drug costs (paralleling GLP-1 RA pricing).
Evidence Maturity (revised): Validated (phase 2b) → heading toward Potentially Practice-Changing pending phase 3 confirmation.
OpenClaw triage_score: 9 | Phase 2 composite: (8×0.30) + (8×0.25) + (7×0.20) + (5×0.15) + (7×0.10) = 7.45
Article 2 — Trevogrumab ± Garetosmab for Muscle Preservation During Semaglutide (COURAGE trial) | PMID 43014326
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First RCT proof-of-concept that anti-myostatin (GDF8 inhibition) preserves lean mass specifically in the context of GLP-1–induced weight loss. This is a genuinely new therapeutic paradigm addressing the leading clinical concern about GLP-1 RA therapy at scale. |
| Clinical Relevance | 8 | Muscle loss during GLP-1 RA therapy is a recognized clinical problem affecting functional outcomes, especially in older adults. This provides actionable phase 2 data, though not yet standard of care. |
| Population Reach | 9 | GLP-1 RAs are now used by tens of millions globally for obesity/T2D; the muscle-preservation question applies to virtually all long-term users. |
| Implementation Speed | 5 | Phase 2 proof-of-concept; needs phase 3 for regulatory approval. 4–7 year timeline realistic. Combination regimen complexity and injectable administration add barriers. |
| Evidence Strength | 7 | Well-powered n=605 RCT, double-blind, placebo-controlled, published in The Lancet. Main limitation: phase 2 only; long-term functional outcomes (falls, frailty, mortality) not yet demonstrated; abstract only reviewed. |
Key quantitative result: Trevogrumab monotherapy established proof-of-concept for lean mass preservation; combination with garetosmab had additional lean mass benefit but worsened adverse events.
External validation: None yet; single trial.
Main limitation: Phase 2 scale; no functional outcome data (muscle mass ≠ functional strength necessarily); garetosmab arm raised safety signals.
Equity implications: Older adults, women (who lose proportionally more lean mass), and low-income patients who may not access combination biologics are most affected. The lean mass preservation benefit could be especially important for older patients with sarcopenic obesity.
Evidence Maturity (revised): Validated → Potentially Practice-Changing (pending phase 3).
OpenClaw triage_score: 9 | Phase 2 composite: (8×0.30) + (9×0.25) + (9×0.20) + (5×0.15) + (7×0.10) = 7.90
Article 3 — Interventions to Reduce Paediatric Cancer Treatment Abandonment in LMICs | PMID 43014336 🟡
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Systematic review synthesizes existing programs; individual interventions (financial support, navigation, education) are individually known. The novelty lies in the pooled quantification of a 67% reduction across 24 studies. |
| Clinical Relevance | 8 | Treatment abandonment is the leading cause of avoidable childhood cancer death in LMICs, estimated to affect >50,000 children/year. A pooled 67% reduction, if real, is clinically transformative. |
| Population Reach | 8 | Affects hundreds of thousands of children with cancer in LMICs annually; structured programs could scale across dozens of countries. Relative to the relevant population (pediatric cancer patients in LMICs), reach is very high. |
| Implementation Speed | 7 | Interventions are largely non-pharmacological (financial aid, navigation, family education) and are already in use in various centers. Existing programs could be scaled rapidly with health system investment. |
| Evidence Strength | 6 | Systematic review of 24 studies is a meaningful synthesis, but heterogeneity and methodological limitations (explicitly noted) reduce certainty. No RCTs likely underlie this; most contributing studies are observational. |
Key quantitative result: Pooled 67% reduction in treatment abandonment across 24 studies (heterogeneity and bias caveats apply).
External validation: Cross-study synthesis serves as indirect validation, but causality across heterogeneous programs is uncertain.
Main limitation: High between-study heterogeneity; methodological quality of underlying studies likely variable; publication bias possible; no randomized evidence.
Equity implications: This article is entirely focused on the most underserved global population in pediatric oncology — children in low- and middle-income countries who face abandonment due to cost, distance, and health literacy barriers. Benefits are concentrated in the highest-need populations. High-income countries are not the target but could learn from navigation models.
Evidence Maturity (revised): Validated (for the synthesis) → In Practice (programs exist and are already deployed).
OpenClaw triage_score: 8 | Phase 2 composite: (8×0.30) + (8×0.25) + (6×0.20) + (7×0.15) + (6×0.10) = 7.25
Article 4 — Newborn Screening for Gaucher Disease, Japan | PMID 43014040 🟡
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | NBS for Gaucher is established in some regions; long-term follow-up cohort data from Japan adds to phenotype characterization but is incremental. |
| Clinical Relevance | 7 | Long-term outcomes data for screen-detected Gaucher patients inform when to initiate enzyme replacement therapy — a live clinical debate. |
| Population Reach | 4 | Gaucher disease is rare (~1/40,000–1/60,000 live births outside Ashkenazi Jewish populations). Relative to the affected population and unmet need, reach is high, but absolute numbers are small. |
| Implementation Speed | 6 | NBS programs for Gaucher exist and are expanding; this data supports policy decisions at a regional/national level. |
| Evidence Strength | 6 | Longitudinal cohort with long-term follow-up is appropriate for this question. Limited by regional scope (Kumamoto/Fukuoka), small absolute numbers, and abstract-only access. |
Key quantitative result: Broad phenotypic spectrum identified; longitudinal outcomes described (specific numbers not available from abstract).
Main limitation: Regional single-country scope; sample size not reported in abstract; phenotypic heterogeneity complicates generalizable treatment guidance.
Equity implications: NBS programs are absent in most LMICs; Gaucher disease is enriched in Ashkenazi Jewish populations (1/800) but underdiagnosed globally in non-European ancestry groups.
Evidence Maturity: Validated.
OpenClaw triage_score: 8 | Phase 2 composite: (7×0.30) + (4×0.25) + (6×0.20) + (6×0.15) + (6×0.10) = 5.80
Article 5 — SPROUT Guidelines for Molecular Profiling, Pediatric Solid Tumors | PMID 43013345 🟢
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Consensus guidelines synthesize existing evidence rather than generating new data. The standardization itself is valuable, but the science is consolidation. |
| Clinical Relevance | 8 | Molecular profiling in pediatric oncology is transforming treatment selection; a formal AACR-endorsed framework directly changes institutional practice and reduces geographic variation. |
| Population Reach | 6 | Pediatric solid tumors: ~16,000 new cases/year in the U.S. alone; globally much higher. Guideline adoption multiplies reach across treatment centers. |
| Implementation Speed | 8 | Guidelines are immediately adoptable; institutions already doing molecular profiling can align protocols now. AACR imprimatur accelerates uptake. |
| Evidence Strength | 6 | Expert consensus is the appropriate design for standardization, but it cannot exceed the evidence base behind it. Strength depends on the quality of underlying studies. |
Main limitation: Consensus guidelines reflect the views of a predominantly U.S./high-income-country expert panel; applicability to low-resource settings is limited.
Equity implications: Standardization could reduce variation within high-resource settings but widens the gap with low-resource settings where molecular profiling is unavailable. The guidelines acknowledge this tension (inferred).
Evidence Maturity: Validated → In Practice.
OpenClaw triage_score: 8 | Phase 2 composite: (8×0.30) + (6×0.25) + (5×0.20) + (8×0.15) + (6×0.10) = 6.70
Article 6 — Oral Semaglutide and Recurrent MACE in T2D (SOUL Trial Secondary Analysis) | PMID 43013292
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | The parent SOUL trial demonstrated CV benefit of oral semaglutide. This secondary analysis extends findings to recurrent events (total event burden), which is a meaningful but incremental contribution. |
| Clinical Relevance | 8 | Reducing total MACE burden (not just first events) has real patient-level and health-economic significance. Oral formulation is a differentiator from injectable GLP-1 RAs and addresses adherence barriers. |
| Population Reach | 9 | ~537 million people globally have T2D; a large fraction have high CV risk and are candidates for this therapy class. |
| Implementation Speed | 7 | Oral semaglutide is already approved (Rybelsus); this secondary analysis could immediately inform prescribing and formulary decisions without new regulatory steps. |
| Evidence Strength | 6 | Secondary analysis of a large (n=9,650) RCT — well-powered but inherits the limitations of secondary/post-hoc analysis (multiplicity, pre-specified vs. exploratory). |
Key quantitative result: Oral semaglutide reduced first plus subsequent 3-P MACE vs. placebo (specific RRR not available from abstract).
Main limitation: Secondary analysis; total event analysis may not have been a pre-specified primary endpoint; abstract only.
Equity implications: Oral formulation is more accessible than injectables in settings with needle-phobia, infrastructure challenges, or caregiver dependency. Cost remains the dominant access barrier globally.
Evidence Maturity (revised): Validated → Potentially Practice-Changing for prescribing in high-CV-risk T2D.
OpenClaw triage_score: 8 | Phase 2 composite: (8×0.30) + (9×0.25) + (6×0.20) + (7×0.15) + (6×0.10) = 7.50
Article 7 — Postoperative ctDNA for Residual Disease in PDAC (Systematic Review/Meta-Analysis) | PMID 43013192
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ctDNA monitoring post-operatively in PDAC is an active but established research area. This meta-analysis consolidates the evidence; incremental rather than groundbreaking. |
| Clinical Relevance | 7 | Pancreatic cancer has a 5-year survival of ~12%; identifying residual disease after curative-intent surgery would meaningfully guide adjuvant therapy decisions. The key limitation (negative ctDNA ≠ no residual disease) tempers clinical impact. |
| Population Reach | 6 | |
| Implementation Speed | 5 | ctDNA platforms exist but are not standard of care post-PDAC resection. Prospective interventional trials needed before practice change. |
| Evidence Strength | 6 | Systematic review/meta-analysis of 237 patients across multiple studies — small aggregate sample for a cancer this heterogeneous. High methodological variability across ctDNA platforms likely. |
Key quantitative result: ctDNA positivity associated with increased recurrence risk and inferior survival; negative result does not reliably exclude residual disease.
Main limitation: Small aggregate n (237); heterogeneity in ctDNA platforms; no intervention trials demonstrating that acting on ctDNA status improves outcomes.
Equity implications: Tumor-informed ctDNA assays are expensive and require institutional infrastructure; access is concentrated in academic cancer centers in high-income countries.
Evidence Maturity: Validated (for the diagnostic association); not yet Potentially Practice-Changing.
OpenClaw triage_score: 8 | Phase 2 composite: (7×0.30) + (6×0.25) + (6×0.20) + (5×0.15) + (6×0.10) = 6.15
Article 8 — ¹⁷⁷Lu Nanoparticles for Injectable Nanoscale Brachytherapy | PMID 43014598 ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Injectable radiolabeled nanoparticles for localized tumor radiation is a genuinely novel platform; first-in-human imaging component adds translational credibility. |
| Clinical Relevance | 3 | Preclinical platform with first-in-human imaging only; no efficacy, safety, or dosing data in humans yet. Cannot exceed 5 per non-human study rule; imaging feasibility ≠ therapeutic efficacy. |
| Population Reach | 5 | Solid tumors broadly; if validated, could apply across multiple cancer types. Too early to quantify. |
| Implementation Speed | 2 | Early preclinical + initial imaging; phase 1 efficacy trials years away; regulatory path complex for radiolabeled nanoparticles. |
| Evidence Strength | 4 | Mixed species; preclinical tumor retention plus first-in-human imaging feasibility; no therapeutic efficacy data in humans; medium confidence classification. |
Evidence Maturity: Exploratory.
OpenClaw triage_score: 7 | Phase 2 composite: (3×0.30) + (5×0.25) + (7×0.20) + (2×0.15) + (4×0.10) = 4.00
Article 9 — BuTT vs. TBC Conditioning for Autologous SCT in CNS Lymphoma | PMID 43014544
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Comparison of conditioning regimens in CNS lymphoma; relevant clinical question but addressed in a very small single-center retrospective cohort. |
| Clinical Relevance | 5 | CNS lymphoma is rare; mucositis reduction with BuTT is clinically meaningful but study is underpowered and nonrandomized. |
| Population Reach | 3 | CNS lymphoma: ~1,500 new cases/year in the U.S.; very small absolute population. |
| Implementation Speed | 4 | Single-center data; would need multicenter confirmation before practice change. |
| Evidence Strength | 3 | n=18; retrospective; single center; nonrandomized. Very limited evidentiary weight. |
Evidence Maturity: Exploratory.
OpenClaw triage_score: 7 | Phase 2 composite: (5×0.30) + (3×0.25) + (5×0.20) + (4×0.15) + (3×0.10) = 4.15
Article 10 — Deep Learning MRI → PET Phenotype Estimation in Alzheimer's Disease | PMID 43014489
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Using structural MRI to impute multi-tracer PET phenotypes (amyloid/tau/neurodegeneration) is conceptually novel and addresses real-world PET access constraints. |
| Clinical Relevance | 6 | Useful as a screening/research tool where PET is unavailable; explicitly noted by authors as not a PET replacement. Clinical impact contingent on prospective validation. |
| Population Reach | 7 | Alzheimer's disease affects ~55 million people globally; PET access is limited even in high-income countries. The accessibility angle is real. |
| Implementation Speed | 4 | Retrospective validation only (n=991); prospective clinical validation and regulatory approval needed; MRI-to-PET synthetic outputs are scientifically interesting but clinically provisional. |
| Evidence Strength | 6 | Reasonable sample size; retrospective; single-modality design; needs prospective and multicenter validation. |
Evidence Maturity: Exploratory.
OpenClaw triage_score: 7 | Phase 2 composite: (6×0.30) + (7×0.25) + (7×0.20) + (4×0.15) + (6×0.10) = 6.00
Article 11 — AI for Pathological Complete Response in Esophageal Cancer (Systematic Review/Meta-Analysis) | PMID 43013774
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI-based imaging for treatment response prediction is a well-established research area; this meta-analysis summarizes it for esophageal cancer specifically. |
| Clinical Relevance | 5 | Authors themselves note wide prediction intervals, bias, and very low certainty preclude routine adoption. The finding is informative about the state of the field rather than clinically actionable now. |
| Population Reach | 5 | Esophageal cancer: ~510,000 deaths globally/year; relevant population for neoadjuvant therapy decisions is substantial. |
| Implementation Speed | 3 | Authors explicitly recommend against routine adoption at this stage. |
| Evidence Strength | 6 | Systematic review/meta-analysis (n=1,891); authors appropriately self-critical about certainty; well-conducted synthesis. |
Evidence Maturity: Validated (as a summary of current evidence state; not Potentially Practice-Changing).
OpenClaw triage_score: 7 | Phase 2 composite: (5×0.30) + (5×0.25) + (5×0.20) + (3×0.15) + (6×0.10) = 4.75
Article 12 — Pharmacogenomic Variation in All of Us Research Program | PMID 43013680
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Thousands of previously unreported pharmacogene variants identified, especially in African and Americas-ancestry populations — genuinely new knowledge with broad implications for precision dosing. |
| Clinical Relevance | 7 | These variants affect drug metabolism across common medications; could directly inform dosing guidelines in underrepresented populations if functionally characterized. |
| Population Reach | 8 | Pharmacogenomics applies across virtually all medication classes; the equity dimension (non-European populations underrepresented in prior databases) is particularly impactful. |
| Implementation Speed | 5 | Discovery phase; functional characterization and clinical guideline updates needed before practice change; existing PGx testing panels would need updating. |
| Evidence Strength | 7 | Large cohort (sample size not specified in abstract but All of Us has >200,000 participants); well-designed population genomics study in Science Translational Medicine. |
Key quantitative result: Thousands of previously unrecognized pharmacogene variants and hundreds of alleles/phenotypes previously unreported or deviating from known frequencies, especially in African and Americas ancestry groups.
Equity implications: This is fundamentally an equity-advancing study — prior PGx databases were heavily European-biased. The findings directly address a gap that leads to inappropriate dosing in non-European patients.
Evidence Maturity: Validated → Potentially Practice-Changing for PGx database curation and future guideline development.
OpenClaw triage_score: 7 | Phase 2 composite: (7×0.30) + (8×0.25) + (8×0.20) + (5×0.15) + (7×0.10) = 7.00
Article 13 — Child Abuse and Dementia Risk — Modifiable Mediators | PMID 43013474
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | The abuse–dementia link has prior evidence; mediation analysis seeking modifiable mediators adds actionable granularity. |
| Clinical Relevance | 6 | Identifying modifiable mediators could point toward prevention targets, but the causal chain is long and intervention evidence is not established here. |
| Population Reach | 7 | Child abuse is widespread globally (~1 billion children affected by maltreatment per WHO); dementia affects ~55 million. The overlap population is large. |
| Implementation Speed | 4 | Mediation findings require interventional testing before clinical implementation; policy change timelines are long. |
| Evidence Strength | 6 | Longitudinal cohort mediation analysis (n=5,448); appropriate design for the question; mediation analyses are inherently assumption-laden. |
Evidence Maturity: Validated (for the association); Exploratory (for modifiable mediator interpretation).
OpenClaw triage_score: 7 | Phase 2 composite: (6×0.30) + (7×0.25) + (6×0.20) + (4×0.15) + (6×0.10) = 5.95
Article 14 — Social Vulnerability Index and CLL Survival, Detroit | PMID 43013361 🟡
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | SVI has been applied to other cancers; application to CLL with a 2× mortality hazard finding is regionally specific but methodologically familiar. |
| Clinical Relevance | 6 | Demonstrates need for targeted outreach and resource allocation; not immediately practice-changing for individual patient management. |
| Population Reach | 5 | CLL is relatively common (~21,000 new U.S. cases/year); the disparity finding has policy relevance across a broader range of hematologic malignancies. |
| Implementation Speed | 5 | Findings could inform outreach programs and resource allocation relatively quickly; changing structural determinants is slow. |
| Evidence Strength | 6 | n=1,406; population-based retrospective cohort; appropriate for disparity research; confounding by treatment access not fully resolvable. |
Key quantitative result: HR ~2.02 for all-cause CLL mortality in highest vs. lowest SVI quartile.
Evidence Maturity: Exploratory.
OpenClaw triage_score: 7 | Phase 2 composite: (6×0.30) + (5×0.25) + (6×0.20) + (5×0.15) + (6×0.10) = 5.60
Article 15 — PMBL Genomic Profiling — Thymic Origin and Aberrant SHM | PMID 43013347
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Confirming thymic B-cell origin and linking aberrant SHM to inferior PFS in PMBL provides mechanistic and prognostic insight that could shape future targeted therapy strategies. |
| Clinical Relevance | 5 | Prognostic value of aberrant SHM is not immediately actionable; no therapeutic target identified yet from abstract. |
| Population Reach | 3 | PMBL is a rare lymphoma subtype (~2–3% of DLBCL; ~500–700 cases/year in the U.S.). |
| Implementation Speed | 3 | Research finding; requires prospective validation and therapeutic development before clinical translation. |
| Evidence Strength | 5 | Multicenter genomic profiling cohort; sample size not reported; abstract only. |
Evidence Maturity: Exploratory.
OpenClaw triage_score: 7 | Phase 2 composite: (5×0.30) + (3×0.25) + (7×0.20) + (3×0.15) + (5×0.10) = 4.60
Article 16 — Economic Modeling of Multimodal Cancer Screening (MRI + Liquid Biopsy) | PMID 43012102
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Modeling studies for multimodal screening economics are not new; this applies existing frameworks to a specific combined modality. |
| Clinical Relevance | 5 | Modeling assumptions drive results; real-world stage shift magnitude is unproven. Useful for policy discussions but not clinically actionable alone. |
| Population Reach | 7 | General population cancer screening; large potential reach if validated. |
| Implementation Speed | 4 | Dependent on clinical validation of screening performance; screening programs require substantial infrastructure. |
| Evidence Strength | 3 | Health-economic modeling; medium confidence; outputs only as reliable as input assumptions; no empirical outcome data. |
Evidence Maturity: Exploratory.
OpenClaw triage_score: 7 | Phase 2 composite: (5×0.30) + (7×0.25) + (5×0.20) + (4×0.15) + (3×0.10) = 5.00
Articles 17–45 — Abbreviated Scoring (Standard Priority)
| Article | PMID | Novelty | Clinical Rel. | Pop. Reach | Impl. Speed | Evid. Strength | Composite |
|---|---|---|---|---|---|---|---|
| Novel Low-Axial Colonic Stent | 43011506 | 5 | 6 | 5 | 5 | 5 | 5.35 |
| Mitoxantrone Liposomes R/R-DLBCL | 43010748 | 5 | 5 | 4 | 4 | 4 | 4.55 |
| Gut Microbiota and Cognition | 43010179 | 7 | 3 | 6 | 2 | 5 | 4.50 |
| AI PE Detection on CT | 43015201 | 5 | 5 | 6 | 3 | 4 | 4.75 |
| RCC Biomarker Review | 43015135 | 4 | 5 | 5 | 3 | 4 | 4.40 |
| ML Tool for Lupus Nephritis Response | 43015004 | 6 | 6 | 5 | 4 | 5 | 5.35 |
| Molecular Neuroimaging AD (Review) | 43014985 | 3 | 5 | 6 | 4 | 4 | 4.50 |
| GLP-1 in MASH (Review) | 43014742 | 3 | 5 | 7 | 5 | 3 | 4.65 |
| HCC Immunoprofiling Multi-Omics | 43014538 | 6 | 4 | 5 | 3 | 4 | 4.45 |
| AI Spine MRI Stenosis Grading | 43014415 | 4 | 3 | 5 | 2 | 4 | 3.60 |
| Automated Cephalometric Landmarks | 43014110 | 4 | 3 | 4 | 4 | 4 | 3.65 |
| CEUS-Targeted Liquid Biopsy ctDNA | 43013996 | 6 | 4 | 4 | 2 | 3 | 3.90 |
| UHRF1 in ATLL Prognosis | 43013712 | 5 | 4 | 2 | 2 | 4 | 3.60 |
| tRNA-Synthetase Variants/AlphaMissense | 43013562 | 5 | 3 | 3 | 2 | 4 | 3.45 |
| DOAC Pharmacogenomics Review | 43013458 | 4 | 5 | 7 | 3 | 4 | 4.80 |
| Insulin Resistance & White Matter (Biobank) | 43012895 | 5 | 5 | 7 | 3 | 5 | 5.00 |
| Smart Tech and Medication Adherence | 43012776 | 4 | 5 | 7 | 5 | 3 | 4.90 |
| GLP-1 Therapy Review (Holst) | 43011228 | 3 | 5 | 8 | 6 | 3 | 4.90 |
| Chinese Population Immune Aging | 43010539 | 5 | 3 | 5 | 2 | 4 | 3.80 |
| Emerging Neurodegen. Diseases (Review) | 43014987 | 4 | 4 | 6 | 3 | 3 | 4.05 |
| CAR-T in Community Settings | 43014547 | 4 | 6 | 5 | 6 | 4 | 5.10 |
| Ultra-processed Food & Cardiometabolic Risk | 43014519 | 4 | 5 | 8 | 5 | 5 | 5.35 |
| Nanomicelles PDT Esophageal Cancer | 43013848 | 6 | 2 | 4 | 1 | 3 | 3.15 |
| Bacteroidetes & HCC Immunotherapy Resistance | 43013741 | 7 | 3 | 5 | 2 | 4 | 3.95 |
| AI Drug Discovery (Dual-Teacher) | 43013436 | 5 | 2 | 4 | 1 | 3 | 3.00 |
| Gene Therapy Awareness, Sickle Cell, Saudi Arabia | 43011792 | 3 | 4 | 5 | 4 | 4 | 3.90 |
| AE Reporting Rare Diseases, South Africa | 43011156 | 3 | 3 | 4 | 4 | 3 | 3.25 |
| Magnetic CTC Isolation for Multi-Omics | 43010450 | 6 | 3 | 4 | 2 | 4 | 3.70 |
| EV-Based Breast Cancer Liquid Biopsy | 43010441 | 6 | 3 | 5 | 2 | 3 | 3.75 |